
Sign up to save your podcasts
Or


With me today is Dr. Mark Pimentel who really needs no introduction to the SIBO community. He's the executive director of the MAST program or Medically Associated Science and Technology. He's professor of medicine at Geffen School of Medicine at Cedar-Sinai Medical Center in L.A. A few of Dr. Pimentel's most significant accomplishments include the discovery of rifaximin as a treatment for IBS. He also developed the first blood test for IBS based on IBS being derived from acute gastroenteritis; the antibody testing. He described the association between IBS and bacterial overgrowth, which forms the basis of microbiome therapies in this condition, as well as uncovering that methanogens are causing constipations in humans.
By Dr Nirala Jacobi4.7
115115 ratings
With me today is Dr. Mark Pimentel who really needs no introduction to the SIBO community. He's the executive director of the MAST program or Medically Associated Science and Technology. He's professor of medicine at Geffen School of Medicine at Cedar-Sinai Medical Center in L.A. A few of Dr. Pimentel's most significant accomplishments include the discovery of rifaximin as a treatment for IBS. He also developed the first blood test for IBS based on IBS being derived from acute gastroenteritis; the antibody testing. He described the association between IBS and bacterial overgrowth, which forms the basis of microbiome therapies in this condition, as well as uncovering that methanogens are causing constipations in humans.

792 Listeners

7,200 Listeners

7,366 Listeners

1,543 Listeners

704 Listeners

786 Listeners

1,688 Listeners

9,246 Listeners

8,893 Listeners

1,816 Listeners

374 Listeners

158 Listeners

1,401 Listeners

799 Listeners

231 Listeners